palopegteriparatide · Yorvipath

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Hypoparathyroidism

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
UK
  • Chronic hypoparathyroidism in adults (Great Britain)
Product first approved 2024medthority.com
EU
  • Adults with chronic hypoparathyroidism
Product first approved 2023EMA
JP
  • Hypoparathyroidism (Teijin Pharma)
tipranks.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Hypoparathyroidism
NCT05387070 · Visen Pharmaceuticals (Shanghai) Co., Ltd.
2021-07-28 – 2026-01-08 · Hypoparathyroidism, Parathyroid Hormone Deficiency, Endocrine System Diseases, Parathyroid Diseases
What this study did
Phase 2 (1)
Hypoparathyroidism
NCT04009291 · Ascendis Pharma A/S
2019-08-27 – 2025-04-17 · Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
What this study did

Competitive landscape

This drug's own stage for Hypoparathyroidism: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Palopegteriparatide (Yorvipath): this drugApprovedPeptidePTH1 receptor (PTH replacement)Reliable signal
NCT04701203: Efficacy - Primary Endpoint During the Blinded Period (26 weeks): TransCon PTH 78.7 Percentage of participants (95% CI 66.3 to 88.1) | Placebo 4.8 Percentage of participants (95% CI 0.1 to 23.8)
EneboparatidePhase 3PeptideParathyroid hormone receptor 1 (PTH1R)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Yorvipath (palopegteriparatide) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
Phase 3HypoparathyroidismRecruiting
Est. primary completion 2027-06 · NCT07081997 · CT.gov ↗
What to watch
August 2027 (1)
Phase 3HypoparathyroidismRecruiting
Est. primary completion 2027-08 · NCT07706764 · CT.gov ↗
What to watch

See the full readout calendar ↗